Skip to Content

Press Releases

Press Releases

Aug 07 2020
Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering
JERUSALEM , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Aspire”) for the purchase and sale, in a registered direct offering, of 7,125,000 of the Company’s
Aug 05 2020
Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
JERUSALEM , Aug. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the second quarter ended June 30, 2020 and provides a corporate update.  "We have worked diligently over the past quarter to address the challenges of an
May 28 2020
Intec Pharma to Present at Jefferies Virtual Healthcare Conference
JERUSALEM , May 28, 2020 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare Conference . Jefferies Virtual Healthcare Conference Date: June 2 – June 4, 2020 Company Presentation:
May 11 2020
Intec Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update
JERUSALEM , May 11, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the first quarter ended March 31, 2020 and provides a corporate update.  Highlights from the Quarter and Recent Weeks Announced that the Accordion Pill (AP)
May 04 2020
Intec Pharma Announces $5.0 Million Registered Direct Offering
JERUSALEM , May 04, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 16,291,952 of the Company’s ordinary shares, at a
Mar 13 2020
Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update
JERUSALEM , March 13, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 and provides a corporate update.  Highlights from the Quarter and Recent Weeks Developed an Accordion Pill
Feb 25 2020
Intec Pharma to Participate at Three Investment Conferences in March
JERUSALEM , Feb. 25, 2020 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 40th Annual Health Care Conference Date: March 2-5, 2020 Company
Jan 30 2020
Intec Pharma Announces Pricing of $6.5 Million Public Offering
JERUSALEM , Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu
Jan 30 2020
Intec Pharma Announces Proposed Public Offering
JERUSALEM , Jan. 30, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares in
Jan 09 2020
Intec Pharma Issues Letter to Shareholders
JERUSALEM , Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill ® platform, in a Letter to Shareholders.
Displaying 1 - 10 of 111